Associated Papers
Non-MPL-W515K/L mutations in myeloproliferative neoplasms: Insights from two case reports and a review of the literature.
Tønne Nesse AS et al.
Expert Review of Hematology, 2025
Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations.
Kandarpa M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
38386293 (PubMed )
Supplement: ccr-23-0372_supplemental_table_2_suppst2.xlsx › Suppl._Table_2
Clinical laboratory characteristics and gene mutation spectrum of Ph-negative MPN patients with atypical variants of JAK2, MPL, or CALR.
Wang Z et al.
Cancer Medicine, 2024
Identification of putative noncanonical driver mutations in patients with essential thrombocythemia.
Arai A et al.
European Journal of Haematology, 2023
Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms.
Zuo Z et al.
Biology, 2022
36671709 (PubMed )
Supplement: biology-12-00013-s001.zip › biology-2072813-supplementary.xlsx › Suppl_tbl_Vaf
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C et al.
Annals of Hematology, 2021
STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms.
Qu S et al.
Leukemia & Lymphoma, 2021
Concomitant and noncanonical JAK2 and MPL mutations in JAK2V617F- and MPLW515 L-positive myelofibrosis.
Schulze S et al.
Genes, Chromosomes & Cancer, 2019
Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
Zuo Z et al.
Current Hematologic Malignancy Reports, 2019
Two activating mutations of MPL in triple-negative myeloproliferative neoplasms.
Xie J et al.
Cancer Medicine, 2019
MPL Y252H anMd PL F126fs mutations in essential thrombocythemia: Case series and review of literature.
Elsayed AG et al.
Hematology Reports, 2019
The Role of New Technologies in Myeloproliferative Neoplasms.
Palumbo GA et al.
Frontiers in Oncology, 2019
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Schischlik F et al.
Expert Review of Hematology, 2017
Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders-A consensus project of the Italian Society of Hematology.
Guglielmelli P et al.
Leukemia Research, 2017
Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.
Grinfeld J et al.
Haematologica, 2017
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.
Cabagnols X et al.
Blood, 2016
Select a paper to view details